Literature DB >> 22488407

Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.

Masanori Nishi1, Ryosei Nishimura, Nobuhiro Suzuki, Akihisa Sawada, Takayuki Okamura, Naoto Fujita, Rie Kanai, Jun Yano, Souichi Adachi, Takahiro Yasumi, Emiko Sato, Koji Yasutomo, Eiichi Ishii, Shouichi Ohga.   

Abstract

Familial hemophagocytic lymphohistiocytosis (FHL) is a disorder of immune homeostasis characterized by fever, cytopenias, hepatosplenomegaly, and coagulopathy. We studied the outcomes of 13 FHL patients who underwent the first unrelated cord blood transplantation (UCBT) after non-myeloablative conditionings. The major regimen consisted of fludarabine (FLU; n = 12)+melphalan (MEL; n = 11)± low-dose total body irradiation (TBI 2-4 Gy; n = 6). The median age at presentation and period to UCBT were 6 and 5 months, respectively. Central nervous system (CNS) disease developed in one infant at diagnosis, and in two others until UCBT. HLH activity was controlled in all but one at the time of UCBT. Ten patients had early engraftment on median day 21 with no grade >2 treatment-related toxicity and two controllable grade >2 acute GVHD. Two patients with early rejection successfully underwent subsequent UCBT after myeloablative conditioning. Two others had late graft failure following mixed donor chimerism. Two deaths occurred from HLH; early liver failure and late CNS disease. Of 11 FLU+MEL-conditioned patients, the frequency of disease-free complete engraftment was higher for MEL (≥120 mg/m(2) )+TBI, or high-dose MEL (180 mg/m(2) ) than for others (83% vs. 25%, p = 0.036). The FLU+MEL-based non-myeloablative regimen was acceptable for FHL infants undergoing UCBT, although further studies will be needed for confirmation.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488407     DOI: 10.1002/ajh.23190

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.

Authors:  Matthias Felber; Colin G Steward; Karim Kentouche; Anders Fasth; Robert F Wynn; Ulrike Zeilhofer; Veronika Haunerdinger; Benjamin Volkmer; Seraina Prader; Bernd Gruhn; Stephan Ehl; Kai Lehmberg; Daniel Müller; Andrew R Gennery; Michael H Albert; Fabian Hauck; Kanchan Rao; Paul Veys; Moustapha Hassan; Arjan C Lankester; Jana Pachlopnik Schmid; Mathias M Hauri-Hohl; Tayfun Güngör
Journal:  Blood Adv       Date:  2020-05-12

2.  Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis.

Authors:  Russell W Jenkins; Christopher J Clarke; John Thomas Lucas; Munira Shabbir; Bill X Wu; Fabio Simbari; Joan Mueller; Yusuf A Hannun; John Lazarchick; Keisuke Shirai
Journal:  Am J Hematol       Date:  2013-08-30       Impact factor: 10.047

3.  Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.

Authors:  Rebecca A Marsh; Kyle Hebert; Soyoung Kim; Christopher C Dvorak; Victor M Aquino; K Scott Baker; Deepak Chellapandian; Blachy Dávila Saldaña; Christine N Duncan; Michael J Eckrich; George E Georges; Timothy S Olson; Michael A Pulsipher; Shalini Shenoy; Elizabeth Stenger; Mark Vander Lugt; Lolie C Yu; Andrew R Gennery; Mary Eapen
Journal:  J Allergy Clin Immunol       Date:  2021-08-08       Impact factor: 10.793

4.  Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.

Authors:  Yusuke Yamashita; Akinori Nishikawa; Yoshifumi Iwahashi; Masakazu Fujimoto; Izumi Sasaki; Hiroyuki Mishima; Akira Kinoshita; Hiroaki Hemmi; Nobuo Kanazawa; Kouichi Ohshima; Ken-Ichi Imadome; Shin-Ichi Murata; Koh-Ichiro Yoshiura; Tsuneyasu Kaisho; Takashi Sonoki; Shinobu Tamura
Journal:  Int J Hematol       Date:  2019-01-31       Impact factor: 2.490

5.  Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.

Authors:  Kai Lehmberg; Michael H Albert; Rita Beier; Karin Beutel; Bernd Gruhn; Nicolaus Kröger; Roland Meisel; Ansgar Schulz; Daniel Stachel; Wilhelm Woessmann; Gritta Janka; Ingo Müller
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

6.  Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.

Authors:  Akihisa Sawada; Shouichi Ohga; Eiichi Ishii; Masami Inoue; Keiko Okada; Jiro Inagaki; Hiroaki Goto; Nobuhiro Suzuki; Kazutoshi Koike; Yoshiko Atsuta; Ritsuro Suzuki; Hiromasa Yabe; Keisei Kawa; Koji Kato; Koji Yasutomo
Journal:  Int J Hematol       Date:  2013-07-11       Impact factor: 2.490

Review 7.  Towards the targeted management of Chediak-Higashi syndrome.

Authors:  Maria L Lozano; Jose Rivera; Isabel Sánchez-Guiu; Vicente Vicente
Journal:  Orphanet J Rare Dis       Date:  2014-08-18       Impact factor: 4.123

Review 8.  Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment.

Authors:  Eiichi Ishii
Journal:  Front Pediatr       Date:  2016-05-13       Impact factor: 3.418

9.  [Umbilical cord blood transplantation in the treatment of Chediak-Higashi syndrome with hemophagocytic syndrome: a case report and literature review].

Authors:  Y Zhang; Z Y Gao; X J Yu; D P Lu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

Review 10.  Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies.

Authors:  Jong Jin Seo
Journal:  Blood Res       Date:  2015-09-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.